Sort
48,018 grants matching “immunotherapy”
Immunotherapy via engineered therapeutic programs in tumors using RNA
$653,455Ron Weiss · Massachusetts Institute Of Technology · U01 · FY2021 · CA
Causes and Consequences of Adenosine Signaling in Pancreatic Cancer
$653,452Timothy R Donahue · University Of California Los Angeles · R01 · FY2024 · CA
Personalized vaccine for patients with AML
$653,338David E Avigan · Beth Israel Deaconess Medical Center · R01 · FY2022 · CA
Body composition and the obesity paradox in clear cell renal cell carcinoma
$653,307Anna Helena Furberg-Barnes · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Three-dimensional conformation changes associated with T cell memory and autoimmunity
$653,282Raymond David Hawkins · University Of Washington · U01 · FY2020 · DK
Defining immune-evasive mechanical signaling in head and neck cancer
$653,172Xaralabos Varelas · Boston University Medical Campus · R01 · FY2024 · DE
Body composition and the obesity paradox in clear cell renal cell carcinoma
$653,156Anna Helena Furberg-Barnes · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Defining the role of cytomegalovirus in glioblastoma therapies
$653,127Sean Edward Lawler · Brown University · R01 · FY2025 · CA
Tunneling Nanotube Inhibitors for Cancer Immunotherapy
$653,121Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2025 · CA
Training Program in Basic Cancer Research
$653,068Wistar Institute · T32 · FY2005 · CA
Developmental Funds
$653,035Thomas P Loughran · University Of Virginia · P30 · FY2021 · CA
Developmental Funds
$653,035Thomas P Loughran · University Of Virginia · P30 · FY2020 · CA
SVEU - CORE ACTIVITIES: ADMINISTRATIVE AND TECHNICAL SUPPORT
$653,017Mark Lewis · Bioqual, Inc. · N01 · FY2018 · AI
Optimizing TCR-CD3 signaling for immunotherapy of cancer
$652,880Michelle Krogsgaard · New York University School Of Medicine · R01 · FY2024 · CA
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer
$652,880Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2025 · CA
Determinants of differentiation and maintenance of PD-1+ CD8 T cells
$652,855Alice Oliffson Kamphorst · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · AI
Determinants of differentiation and maintenance of PD-1+ CD8 T cells
$652,855Alice Oliffson Kamphorst · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · AI
Determinants of differentiation and maintenance of PD-1+ CD8 T cells
$652,855Alice Oliffson Kamphorst · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · AI
Determinants of differentiation and maintenance of PD-1+ CD8 T cells
$652,855Alice Oliffson Kamphorst · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · AI
Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma
$652,851Marcela Valderrama Maus · Massachusetts General Hospital · R01 · FY2025 · CA
Local microbiota signatures of pro-tumor immunity and checkpoint inhibition susceptibility in lung cancer
$652,794Leopoldo Nicolas Segal · New York University School Of Medicine · R37 · FY2022 · CA
Development of First-in-Class RIPK1 Degraders to Improve Cancer Immunotherapies
$652,762Jin Wang · Baylor College Of Medicine · R01 · FY2022 · CA
Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma
$652,725Marcela Valderrama Maus · Massachusetts General Hospital · R01 · FY2024 · CA
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
$652,695Pawel K. Mazur · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Tunneling Nanotube Inhibitors for Cancer Immunotherapy
$652,634Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2023 · CA